Axsome Therapeutics公司股价今日盘中大跌5.41%,引发了市场的广泛关注。这与公司2024年第四季度财报表现未达预期密切相关。
公司此前公布的季度财报显示,每股亏损为1.54美元,远低于分析师普遍预期的1.03美元亏损。尽管相比去年同期每股亏损2.08美元有所改善,但错失市场预期成为打击。另一方面,公司季度销售额达到11.877亿美元,虽然小幅超出11.764亿美元的预期,但同比增长66.03%的增速未能令投资者满意。
财报表现令公司基本面遭到质疑,资金持续流出,引发股价大幅下挫。未来公司能否通过扩大销售规模和控制成本来扭转亏损局面,将决定其盈利能力和股价表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.